img

Global Biosimilars of Rituximab Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Biosimilars of Rituximab Market Insights, Forecast to 2034

Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.
Global Biosimilars of Rituximab market is expected to reach to US$ 1952 million in 2024, with a positive growth of %, compared with US$ 1774 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Biosimilars of Rituximab industry is evaluated to reach US$ 3184.6 million in 2029. The CAGR will be 8.5% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Biosimilars of Rituximab market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Biosimilars of Rituximab market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy’s Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Viatris
Probiomed
TRPharma
Zenotech Laboratories
Segment by Type
500mg
100mg
Other

Segment by Application


Hospital Pharmacy
Retail Pharmacy

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Biosimilars of Rituximab plant distribution, commercial date of Biosimilars of Rituximab, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Biosimilars of Rituximab introduction, etc. Biosimilars of Rituximab Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Biosimilars of Rituximab
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Biosimilars of Rituximab Product Introduction
1.2 Market by Type
1.2.1 Global Biosimilars of Rituximab Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 500mg
1.2.3 100mg
1.2.4 Other
1.3 Market by Application
1.3.1 Global Biosimilars of Rituximab Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biosimilars of Rituximab Sales Estimates and Forecasts 2018-2029
2.2 Global Biosimilars of Rituximab Revenue by Region
2.2.1 Global Biosimilars of Rituximab Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Biosimilars of Rituximab Revenue by Region (2018-2024)
2.2.3 Global Biosimilars of Rituximab Revenue by Region (2024-2029)
2.2.4 Global Biosimilars of Rituximab Revenue Market Share by Region (2018-2029)
2.3 Global Biosimilars of Rituximab Sales Estimates and Forecasts 2018-2029
2.4 Global Biosimilars of Rituximab Sales by Region
2.4.1 Global Biosimilars of Rituximab Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Biosimilars of Rituximab Sales by Region (2018-2024)
2.4.3 Global Biosimilars of Rituximab Sales by Region (2024-2029)
2.4.4 Global Biosimilars of Rituximab Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Biosimilars of Rituximab Sales by Manufacturers
3.1.1 Global Biosimilars of Rituximab Sales by Manufacturers (2018-2024)
3.1.2 Global Biosimilars of Rituximab Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biosimilars of Rituximab in 2022
3.2 Global Biosimilars of Rituximab Revenue by Manufacturers
3.2.1 Global Biosimilars of Rituximab Revenue by Manufacturers (2018-2024)
3.2.2 Global Biosimilars of Rituximab Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Biosimilars of Rituximab Revenue in 2022
3.3 Global Key Players of Biosimilars of Rituximab, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Biosimilars of Rituximab Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Biosimilars of Rituximab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Biosimilars of Rituximab, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Biosimilars of Rituximab, Product Offered and Application
3.8 Global Key Manufacturers of Biosimilars of Rituximab, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Biosimilars of Rituximab Sales by Type
4.1.1 Global Biosimilars of Rituximab Historical Sales by Type (2018-2024)
4.1.2 Global Biosimilars of Rituximab Forecasted Sales by Type (2024-2029)
4.1.3 Global Biosimilars of Rituximab Sales Market Share by Type (2018-2029)
4.2 Global Biosimilars of Rituximab Revenue by Type
4.2.1 Global Biosimilars of Rituximab Historical Revenue by Type (2018-2024)
4.2.2 Global Biosimilars of Rituximab Forecasted Revenue by Type (2024-2029)
4.2.3 Global Biosimilars of Rituximab Revenue Market Share by Type (2018-2029)
4.3 Global Biosimilars of Rituximab Price by Type
4.3.1 Global Biosimilars of Rituximab Price by Type (2018-2024)
4.3.2 Global Biosimilars of Rituximab Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Biosimilars of Rituximab Sales by Application
5.1.1 Global Biosimilars of Rituximab Historical Sales by Application (2018-2024)
5.1.2 Global Biosimilars of Rituximab Forecasted Sales by Application (2024-2029)
5.1.3 Global Biosimilars of Rituximab Sales Market Share by Application (2018-2029)
5.2 Global Biosimilars of Rituximab Revenue by Application
5.2.1 Global Biosimilars of Rituximab Historical Revenue by Application (2018-2024)
5.2.2 Global Biosimilars of Rituximab Forecasted Revenue by Application (2024-2029)
5.2.3 Global Biosimilars of Rituximab Revenue Market Share by Application (2018-2029)
5.3 Global Biosimilars of Rituximab Price by Application
5.3.1 Global Biosimilars of Rituximab Price by Application (2018-2024)
5.3.2 Global Biosimilars of Rituximab Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Biosimilars of Rituximab Market Size by Type
6.1.1 US & Canada Biosimilars of Rituximab Sales by Type (2018-2029)
6.1.2 US & Canada Biosimilars of Rituximab Revenue by Type (2018-2029)
6.2 US & Canada Biosimilars of Rituximab Market Size by Application
6.2.1 US & Canada Biosimilars of Rituximab Sales by Application (2018-2029)
6.2.2 US & Canada Biosimilars of Rituximab Revenue by Application (2018-2029)
6.3 US & Canada Biosimilars of Rituximab Market Size by Country
6.3.1 US & Canada Biosimilars of Rituximab Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Biosimilars of Rituximab Sales by Country (2018-2029)
6.3.3 US & Canada Biosimilars of Rituximab Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Biosimilars of Rituximab Market Size by Type
7.1.1 Europe Biosimilars of Rituximab Sales by Type (2018-2029)
7.1.2 Europe Biosimilars of Rituximab Revenue by Type (2018-2029)
7.2 Europe Biosimilars of Rituximab Market Size by Application
7.2.1 Europe Biosimilars of Rituximab Sales by Application (2018-2029)
7.2.2 Europe Biosimilars of Rituximab Revenue by Application (2018-2029)
7.3 Europe Biosimilars of Rituximab Market Size by Country
7.3.1 Europe Biosimilars of Rituximab Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Biosimilars of Rituximab Sales by Country (2018-2029)
7.3.3 Europe Biosimilars of Rituximab Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Biosimilars of Rituximab Market Size
8.1.1 China Biosimilars of Rituximab Sales (2018-2029)
8.1.2 China Biosimilars of Rituximab Revenue (2018-2029)
8.2 China Biosimilars of Rituximab Market Size by Application
8.2.1 China Biosimilars of Rituximab Sales by Application (2018-2029)
8.2.2 China Biosimilars of Rituximab Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Biosimilars of Rituximab Market Size by Type
9.1.1 Asia Biosimilars of Rituximab Sales by Type (2018-2029)
9.1.2 Asia Biosimilars of Rituximab Revenue by Type (2018-2029)
9.2 Asia Biosimilars of Rituximab Market Size by Application
9.2.1 Asia Biosimilars of Rituximab Sales by Application (2018-2029)
9.2.2 Asia Biosimilars of Rituximab Revenue by Application (2018-2029)
9.3 Asia Biosimilars of Rituximab Sales by Region
9.3.1 Asia Biosimilars of Rituximab Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Biosimilars of Rituximab Revenue by Region (2018-2029)
9.3.3 Asia Biosimilars of Rituximab Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Biosimilars of Rituximab Market Size by Type
10.1.1 Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Biosimilars of Rituximab Market Size by Application
10.2.1 Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Country
10.3.1 Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Overview
11.1.3 Amgen Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Amgen Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Recent Developments
11.2 AryoGen Pharmed
11.2.1 AryoGen Pharmed Company Information
11.2.2 AryoGen Pharmed Overview
11.2.3 AryoGen Pharmed Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 AryoGen Pharmed Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AryoGen Pharmed Recent Developments
11.3 Biocad
11.3.1 Biocad Company Information
11.3.2 Biocad Overview
11.3.3 Biocad Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Biocad Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biocad Recent Developments
11.4 Cadila Pharmaceuticals
11.4.1 Cadila Pharmaceuticals Company Information
11.4.2 Cadila Pharmaceuticals Overview
11.4.3 Cadila Pharmaceuticals Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Cadila Pharmaceuticals Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cadila Pharmaceuticals Recent Developments
11.5 Celltrion
11.5.1 Celltrion Company Information
11.5.2 Celltrion Overview
11.5.3 Celltrion Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Celltrion Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Celltrion Recent Developments
11.6 Dr Reddy’s Laboratories
11.6.1 Dr Reddy’s Laboratories Company Information
11.6.2 Dr Reddy’s Laboratories Overview
11.6.3 Dr Reddy’s Laboratories Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Dr Reddy’s Laboratories Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Dr Reddy’s Laboratories Recent Developments
11.7 Teva
11.7.1 Teva Company Information
11.7.2 Teva Overview
11.7.3 Teva Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Teva Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Teva Recent Developments
11.8 Hetero Group
11.8.1 Hetero Group Company Information
11.8.2 Hetero Group Overview
11.8.3 Hetero Group Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Hetero Group Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Hetero Group Recent Developments
11.9 Innovent Biologics
11.9.1 Innovent Biologics Company Information
11.9.2 Innovent Biologics Overview
11.9.3 Innovent Biologics Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Innovent Biologics Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Innovent Biologics Recent Developments
11.10 Intas Biopharmaceuticals
11.10.1 Intas Biopharmaceuticals Company Information
11.10.2 Intas Biopharmaceuticals Overview
11.10.3 Intas Biopharmaceuticals Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Intas Biopharmaceuticals Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Intas Biopharmaceuticals Recent Developments
11.11 Viatris
11.11.1 Viatris Company Information
11.11.2 Viatris Overview
11.11.3 Viatris Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Viatris Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Viatris Recent Developments
11.12 Probiomed
11.12.1 Probiomed Company Information
11.12.2 Probiomed Overview
11.12.3 Probiomed Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Probiomed Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Probiomed Recent Developments
11.13 TRPharma
11.13.1 TRPharma Company Information
11.13.2 TRPharma Overview
11.13.3 TRPharma Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 TRPharma Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 TRPharma Recent Developments
11.14 Zenotech Laboratories
11.14.1 Zenotech Laboratories Company Information
11.14.2 Zenotech Laboratories Overview
11.14.3 Zenotech Laboratories Biosimilars of Rituximab Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Zenotech Laboratories Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Zenotech Laboratories Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Biosimilars of Rituximab Industry Chain Analysis
12.2 Biosimilars of Rituximab Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilars of Rituximab Production Mode & Process
12.4 Biosimilars of Rituximab Sales and Marketing
12.4.1 Biosimilars of Rituximab Sales Channels
12.4.2 Biosimilars of Rituximab Distributors
12.5 Biosimilars of Rituximab Customers
13 Market Dynamics
13.1 Biosimilars of Rituximab Industry Trends
13.2 Biosimilars of Rituximab Market Drivers
13.3 Biosimilars of Rituximab Market Challenges
13.4 Biosimilars of Rituximab Market Restraints
14 Key Findings in The Global Biosimilars of Rituximab Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Biosimilars of Rituximab Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of 500mg
Table 3. Major Manufacturers of 100mg
Table 4. Major Manufacturers of Other
Table 5. Global Biosimilars of Rituximab Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Biosimilars of Rituximab Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Biosimilars of Rituximab Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Biosimilars of Rituximab Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Biosimilars of Rituximab Revenue Market Share by Region (2018-2024)
Table 10. Global Biosimilars of Rituximab Revenue Market Share by Region (2024-2029)
Table 11. Global Biosimilars of Rituximab Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Biosimilars of Rituximab Sales by Region (2018-2024) & (K Units)
Table 13. Global Biosimilars of Rituximab Sales by Region (2024-2029) & (K Units)
Table 14. Global Biosimilars of Rituximab Sales Market Share by Region (2018-2024)
Table 15. Global Biosimilars of Rituximab Sales Market Share by Region (2024-2029)
Table 16. Global Biosimilars of Rituximab Sales by Manufacturers (2018-2024) & (K Units)
Table 17. Global Biosimilars of Rituximab Sales Share by Manufacturers (2018-2024)
Table 18. Global Biosimilars of Rituximab Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Biosimilars of Rituximab Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Biosimilars of Rituximab, Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Biosimilars of Rituximab Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Biosimilars of Rituximab Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Biosimilars of Rituximab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars of Rituximab as of 2022)
Table 24. Global Key Manufacturers of Biosimilars of Rituximab, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Biosimilars of Rituximab, Product Offered and Application
Table 26. Global Key Manufacturers of Biosimilars of Rituximab, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Biosimilars of Rituximab Sales by Type (2018-2024) & (K Units)
Table 29. Global Biosimilars of Rituximab Sales by Type (2024-2029) & (K Units)
Table 30. Global Biosimilars of Rituximab Sales Share by Type (2018-2024)
Table 31. Global Biosimilars of Rituximab Sales Share by Type (2024-2029)
Table 32. Global Biosimilars of Rituximab Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Biosimilars of Rituximab Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Biosimilars of Rituximab Revenue Share by Type (2018-2024)
Table 35. Global Biosimilars of Rituximab Revenue Share by Type (2024-2029)
Table 36. Biosimilars of Rituximab Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Biosimilars of Rituximab Price Forecast by Type (2024-2029) & (US$/Unit)
Table 38. Global Biosimilars of Rituximab Sales by Application (2018-2024) & (K Units)
Table 39. Global Biosimilars of Rituximab Sales by Application (2024-2029) & (K Units)
Table 40. Global Biosimilars of Rituximab Sales Share by Application (2018-2024)
Table 41. Global Biosimilars of Rituximab Sales Share by Application (2024-2029)
Table 42. Global Biosimilars of Rituximab Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Biosimilars of Rituximab Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Biosimilars of Rituximab Revenue Share by Application (2018-2024)
Table 45. Global Biosimilars of Rituximab Revenue Share by Application (2024-2029)
Table 46. Biosimilars of Rituximab Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Biosimilars of Rituximab Price Forecast by Application (2024-2029) & (US$/Unit)
Table 48. US & Canada Biosimilars of Rituximab Sales by Type (2018-2024) & (K Units)
Table 49. US & Canada Biosimilars of Rituximab Sales by Type (2024-2029) & (K Units)
Table 50. US & Canada Biosimilars of Rituximab Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Biosimilars of Rituximab Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Biosimilars of Rituximab Sales by Application (2018-2024) & (K Units)
Table 53. US & Canada Biosimilars of Rituximab Sales by Application (2024-2029) & (K Units)
Table 54. US & Canada Biosimilars of Rituximab Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Biosimilars of Rituximab Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Biosimilars of Rituximab Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Biosimilars of Rituximab Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Biosimilars of Rituximab Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Biosimilars of Rituximab Sales by Country (2018-2024) & (K Units)
Table 60. US & Canada Biosimilars of Rituximab Sales by Country (2024-2029) & (K Units)
Table 61. Europe Biosimilars of Rituximab Sales by Type (2018-2024) & (K Units)
Table 62. Europe Biosimilars of Rituximab Sales by Type (2024-2029) & (K Units)
Table 63. Europe Biosimilars of Rituximab Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Biosimilars of Rituximab Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Biosimilars of Rituximab Sales by Application (2018-2024) & (K Units)
Table 66. Europe Biosimilars of Rituximab Sales by Application (2024-2029) & (K Units)
Table 67. Europe Biosimilars of Rituximab Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Biosimilars of Rituximab Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Biosimilars of Rituximab Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Biosimilars of Rituximab Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Biosimilars of Rituximab Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Biosimilars of Rituximab Sales by Country (2018-2024) & (K Units)
Table 73. Europe Biosimilars of Rituximab Sales by Country (2024-2029) & (K Units)
Table 74. China Biosimilars of Rituximab Sales by Type (2018-2024) & (K Units)
Table 75. China Biosimilars of Rituximab Sales by Type (2024-2029) & (K Units)
Table 76. China Biosimilars of Rituximab Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Biosimilars of Rituximab Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Biosimilars of Rituximab Sales by Application (2018-2024) & (K Units)
Table 79. China Biosimilars of Rituximab Sales by Application (2024-2029) & (K Units)
Table 80. China Biosimilars of Rituximab Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Biosimilars of Rituximab Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Biosimilars of Rituximab Sales by Type (2018-2024) & (K Units)
Table 83. Asia Biosimilars of Rituximab Sales by Type (2024-2029) & (K Units)
Table 84. Asia Biosimilars of Rituximab Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Biosimilars of Rituximab Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Biosimilars of Rituximab Sales by Application (2018-2024) & (K Units)
Table 87. Asia Biosimilars of Rituximab Sales by Application (2024-2029) & (K Units)
Table 88. Asia Biosimilars of Rituximab Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Biosimilars of Rituximab Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Biosimilars of Rituximab Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Biosimilars of Rituximab Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Biosimilars of Rituximab Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Biosimilars of Rituximab Sales by Region (2018-2024) & (K Units)
Table 94. Asia Biosimilars of Rituximab Sales by Region (2024-2029) & (K Units)
Table 95. Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Type (2018-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Type (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Application (2018-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Application (2024-2029) & (K Units)
Table 101. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Country (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Biosimilars of Rituximab Sales by Country (2024-2029) & (K Units)
Table 108. Amgen Company Information
Table 109. Amgen Description and Major Businesses
Table 110. Amgen Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Amgen Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Amgen Recent Developments
Table 113. AryoGen Pharmed Company Information
Table 114. AryoGen Pharmed Description and Major Businesses
Table 115. AryoGen Pharmed Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. AryoGen Pharmed Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. AryoGen Pharmed Recent Developments
Table 118. Biocad Company Information
Table 119. Biocad Description and Major Businesses
Table 120. Biocad Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Biocad Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Biocad Recent Developments
Table 123. Cadila Pharmaceuticals Company Information
Table 124. Cadila Pharmaceuticals Description and Major Businesses
Table 125. Cadila Pharmaceuticals Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Cadila Pharmaceuticals Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Cadila Pharmaceuticals Recent Developments
Table 128. Celltrion Company Information
Table 129. Celltrion Description and Major Businesses
Table 130. Celltrion Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Celltrion Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Celltrion Recent Developments
Table 133. Dr Reddy’s Laboratories Company Information
Table 134. Dr Reddy’s Laboratories Description and Major Businesses
Table 135. Dr Reddy’s Laboratories Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. Dr Reddy’s Laboratories Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Dr Reddy’s Laboratories Recent Developments
Table 138. Teva Company Information
Table 139. Teva Description and Major Businesses
Table 140. Teva Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Teva Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Teva Recent Developments
Table 143. Hetero Group Company Information
Table 144. Hetero Group Description and Major Businesses
Table 145. Hetero Group Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. Hetero Group Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Hetero Group Recent Developments
Table 148. Innovent Biologics Company Information
Table 149. Innovent Biologics Description and Major Businesses
Table 150. Innovent Biologics Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 151. Innovent Biologics Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Innovent Biologics Recent Developments
Table 153. Intas Biopharmaceuticals Company Information
Table 154. Intas Biopharmaceuticals Description and Major Businesses
Table 155. Intas Biopharmaceuticals Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 156. Intas Biopharmaceuticals Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Intas Biopharmaceuticals Recent Developments
Table 158. Viatris Company Information
Table 159. Viatris Description and Major Businesses
Table 160. Viatris Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 161. Viatris Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. Viatris Recent Developments
Table 163. Probiomed Company Information
Table 164. Probiomed Description and Major Businesses
Table 165. Probiomed Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 166. Probiomed Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. Probiomed Recent Developments
Table 168. TRPharma Company Information
Table 169. TRPharma Description and Major Businesses
Table 170. TRPharma Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 171. TRPharma Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. TRPharma Recent Developments
Table 173. Zenotech Laboratories Company Information
Table 174. Zenotech Laboratories Description and Major Businesses
Table 175. Zenotech Laboratories Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 176. Zenotech Laboratories Biosimilars of Rituximab Product Model Numbers, Pictures, Descriptions and Specifications
Table 177. Zenotech Laboratories Recent Developments
Table 178. Key Raw Materials Lists
Table 179. Raw Materials Key Suppliers Lists
Table 180. Biosimilars of Rituximab Distributors List
Table 181. Biosimilars of Rituximab Customers List
Table 182. Biosimilars of Rituximab Market Trends
Table 183. Biosimilars of Rituximab Market Drivers
Table 184. Biosimilars of Rituximab Market Challenges
Table 185. Biosimilars of Rituximab Market Restraints
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilars of Rituximab Product Picture
Figure 2. Global Biosimilars of Rituximab Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Biosimilars of Rituximab Market Share by Type in 2022 & 2029
Figure 4. 500mg Product Picture
Figure 5. 100mg Product Picture
Figure 6. Other Product Picture
Figure 7. Global Biosimilars of Rituximab Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Biosimilars of Rituximab Market Share by Application in 2022 & 2029
Figure 9. Hospital Pharmacy
Figure 10. Retail Pharmacy
Figure 11. Biosimilars of Rituximab Report Years Considered
Figure 12. Global Biosimilars of Rituximab Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Biosimilars of Rituximab Revenue 2018-2029 (US$ Million)
Figure 14. Global Biosimilars of Rituximab Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 15. Global Biosimilars of Rituximab Revenue Market Share by Region (2018-2029)
Figure 16. Global Biosimilars of Rituximab Sales 2018-2029 ((K Units)
Figure 17. Global Biosimilars of Rituximab Sales Market Share by Region (2018-2029)
Figure 18. US & Canada Biosimilars of Rituximab Sales YoY (2018-2029) & (K Units)
Figure 19. US & Canada Biosimilars of Rituximab Revenue YoY (2018-2029) & (US$ Million)
Figure 20. Europe Biosimilars of Rituximab Sales YoY (2018-2029) & (K Units)
Figure 21. Europe Biosimilars of Rituximab Revenue YoY (2018-2029) & (US$ Million)
Figure 22. China Biosimilars of Rituximab Sales YoY (2018-2029) & (K Units)
Figure 23. China Biosimilars of Rituximab Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Asia (excluding China) Biosimilars of Rituximab Sales YoY (2018-2029) & (K Units)
Figure 25. Asia (excluding China) Biosimilars of Rituximab Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Biosimilars of Rituximab Sales YoY (2018-2029) & (K Units)
Figure 27. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue YoY (2018-2029) & (US$ Million)
Figure 28. The Biosimilars of Rituximab Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 29. The Top 5 and 10 Largest Manufacturers of Biosimilars of Rituximab in the World: Market Share by Biosimilars of Rituximab Revenue in 2022
Figure 30. Global Biosimilars of Rituximab Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Biosimilars of Rituximab Sales Market Share by Type (2018-2029)
Figure 32. Global Biosimilars of Rituximab Revenue Market Share by Type (2018-2029)
Figure 33. Global Biosimilars of Rituximab Sales Market Share by Application (2018-2029)
Figure 34. Global Biosimilars of Rituximab Revenue Market Share by Application (2018-2029)
Figure 35. US & Canada Biosimilars of Rituximab Sales Market Share by Type (2018-2029)
Figure 36. US & Canada Biosimilars of Rituximab Revenue Market Share by Type (2018-2029)
Figure 37. US & Canada Biosimilars of Rituximab Sales Market Share by Application (2018-2029)
Figure 38. US & Canada Biosimilars of Rituximab Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Biosimilars of Rituximab Revenue Share by Country (2018-2029)
Figure 40. US & Canada Biosimilars of Rituximab Sales Share by Country (2018-2029)
Figure 41. U.S. Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 42. Canada Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 43. Europe Biosimilars of Rituximab Sales Market Share by Type (2018-2029)
Figure 44. Europe Biosimilars of Rituximab Revenue Market Share by Type (2018-2029)
Figure 45. Europe Biosimilars of Rituximab Sales Market Share by Application (2018-2029)
Figure 46. Europe Biosimilars of Rituximab Revenue Market Share by Application (2018-2029)
Figure 47. Europe Biosimilars of Rituximab Revenue Share by Country (2018-2029)
Figure 48. Europe Biosimilars of Rituximab Sales Share by Country (2018-2029)
Figure 49. Germany Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 50. France Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 51. U.K. Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 52. Italy Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 53. Russia Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 54. China Biosimilars of Rituximab Sales Market Share by Type (2018-2029)
Figure 55. China Biosimilars of Rituximab Revenue Market Share by Type (2018-2029)
Figure 56. China Biosimilars of Rituximab Sales Market Share by Application (2018-2029)
Figure 57. China Biosimilars of Rituximab Revenue Market Share by Application (2018-2029)
Figure 58. Asia Biosimilars of Rituximab Sales Market Share by Type (2018-2029)
Figure 59. Asia Biosimilars of Rituximab Revenue Market Share by Type (2018-2029)
Figure 60. Asia Biosimilars of Rituximab Sales Market Share by Application (2018-2029)
Figure 61. Asia Biosimilars of Rituximab Revenue Market Share by Application (2018-2029)
Figure 62. Asia Biosimilars of Rituximab Revenue Share by Region (2018-2029)
Figure 63. Asia Biosimilars of Rituximab Sales Share by Region (2018-2029)
Figure 64. Japan Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 65. South Korea Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 66. China Taiwan Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 67. Southeast Asia Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 68. India Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Biosimilars of Rituximab Sales Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Biosimilars of Rituximab Sales Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Biosimilars of Rituximab Revenue Share by Country (2018-2029)
Figure 74. Middle East, Africa and Latin America Biosimilars of Rituximab Sales Share by Country (2018-2029)
Figure 75. Brazil Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 76. Mexico Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 77. Turkey Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 78. Israel Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 79. GCC Countries Biosimilars of Rituximab Revenue (2018-2029) & (US$ Million)
Figure 80. Biosimilars of Rituximab Value Chain
Figure 81. Biosimilars of Rituximab Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries